**大師講堂-失智症研究前沿系列講座 課程表**

**Frontiers in Dementia Research—Master Lectures**

|  |  |
| --- | --- |
| 課程時間 | 112年10月13日 12：30~13：30 |
| 課程地點 | **Webex meeting room**：<https://taipeimedicaluniversityshuanghohospitalministryofhealth.my.webex.com/meet/pr1585279471>**meeting room number**：1585 27 9471 |
| 主題 | Frontiers in Dementia Research—Master Lectures |
| 講師 | Prof. Marwan Noel Sabbagh  |
| 講師簡歷 | **Affiliation(s):** Marwan Sabbagh, MD, is a behavioral neurologist in the Alzheimer’s and Memory Disorders Program at Barrow Neurological Institute. He is also a professor and the Vice Chair of Research in the Institute’s Department of Neurology. He is board certified in neurology by the American Board of Psychiatry and Neurology.Dr. Sabbagh’s expertise includes the diagnosis and treatment of Alzheimer’s disease and other memory disorders. He is a fellow of the American Academy of Neurology.Dr. Sabbagh earned his medical degree from the University of Arizona College of Medicine in Tucson and his undergraduate degree from the University of California—Berkeley. He completed his neurology residency at Baylor College of Medicine in Houston, Texas, and a geriatric neurology and dementia fellowship at the University of California San Diego School of Medicine.Dr. Sabbagh is a leading investigator of many prominent national Alzheimer’s prevention and treatment clinical trials. He serves on the editorial boards of the Journal of Alzheimer’s Disease and Alzheimer’s and Dementia: Translational Research & Clinical Interventions. He is the editor-in-chief of Neurology and Therapy. Dr. Sabbagh is a prolific author who has written and edited books on Alzheimer’s disease and has contributed to hundreds of medical and scientific articles. |
| 課程摘要 | The first disease modifying therapies (DMTs) have been shown to have clinical efficacy in slowing the rate of decline in Alzheimer's disease. These include aducanumab, lecanemab and donanemab. These biological drugs are monoclonal antibodies designed to target and remove amyloid. To date, their efficacy signal is limited to mild cognitive impairment or mild dementia due to AD. In order for a patient to receive these drugs, the provider will need to assess the patient, make a clinical diagnosis, exclude other pathology and abnormalities by MRI, and confirm with biomarkers. The biomarkers required for confirmation include CSF, and PET but might include plasma in the future. Disease specific biomarkers include amyloid, total tau, phosphorylated tau and neurofilament light. AD is beginning the transformation from a terminal disease to a chronic disease |
| 課程形式 | 課程時長1小時 (12:30~13:30)Date: October 13th, 2023Agenda:12:30-12:35: Opening (online meeting room opens at 12:20 p.m.)12:35-13:15: Current and future developments in Alzheimer's research and treatment13:15-13:30: Q&A session |
| 主辦單位 | 衛生福利部雙和醫院(臺北醫學大學興建經營) 失智症中心 |
| 協辦單位 | 衛采製藥股份有限公司臺灣神經學學會臺北榮民總醫院神經內科臺中榮民總醫院失智症中心臺北市立聯合醫院失智症中心臺北醫學大學醫學院 |
| 聯絡人 | 黃立楷 (雙和醫院 失智症中心) |
| 聯絡方式 | 0970746913 greatoriole@gmail.com |